secwatch.observer — SEC 8-K summary
======================================

Issuer:     RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK:        0001649904
Form:       8-K
Filed at:   2026-03-26T23:59:59+00:00
Accession:  0001628280-26-021414
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rhythm Pharma gets positive CHMP opinion to expand IMCIVREE label for acquired hypothalamic obesity
--------------------------------------------------------------------------------

- CHMP recommends expanding IMCIVREE (setmelanotide) marketing authorization to treat obesity/control hunger in patients >=4 years with acquired HO due to hypothalamic injury.
- European Commission decision on label expansion anticipated in Q2 2026.
- Follows FDA approval last week; CEO cites broad label and global drug development approach.
- Acquired HO is a rare neuroendocrine disease with impaired MC4R pathway signaling causing rapid weight gain and hyperphagia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649904/000162828026021414/0001628280-26-021414-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649904/000162828026021414/rytm-20260326.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-021414

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer